Netherlands· NL-2b188cfbb35a
Minims Pilocarpinenitraat 20 mg/ml, oogdruppels, oplossing
A pilocarpine product containing pilocarpine nitraat, registered in Netherlands by Bausch + Lomb Ireland Limited. The same ATC class is registered in 10 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Pilocarpine is registered in 10 of 19 countries.
Countries holding a registration under ATC S01EB01 (pilocarpine), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 6 of them publish a price we can compare per daily dose
Pilocarpine · ATC S01EB01
10 / 19 countries
- Belgiumprice
- Canada
- Finlandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- PILOCARPINE NITRAAT
- Manufacturer
- Bausch + Lomb Ireland Limited
- Country
- Netherlands (NL)
- ATC code
- S01EB01
- ATC class
- Pilocarpine
- Defined daily dose
- 0.285 Lamelle
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_id09368
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
50 interactions on record for pilocarpine.
Graded by severity as the source publishes them — 50 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Pilocarpine · interactions on record
50 records
- 50 moderate
Most severe, free to view
- DicycloverineA03AA07moderate
- PropanthelineA03AB05moderate
- MepenzolateA03AB12moderate
- TrospiumA03AB20moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under S01EB01
Pilocarpine, as other registers publish it.
- NorwayDropiltonBruschettini
- FinlandIsopto CarpineNovartis Finland Oy
- FinlandIsopto CarpineNovartis Finland Oy
- CanadaISOPTO CARPINENOVARTIS PHARMACEUTICALS CANADA INC
- FinlandIsopto-CarpineAlcon Couvreur N.V.
- FinlandIsopto-CarpineAlcon Couvreur N.V.
- FinlandMinims Pilocarpine NitrateChauvin Pharmaceuticals Limited
- FinlandMinims Pilocarpine NitrateChauvin Pharmaceuticals Limited
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/604127b2-dd4d-4f90-bc90-66c67b0f99b9 GET /v1/drugs/604127b2-dd4d-4f90-bc90-66c67b0f99b9?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Oogdruppels, oplossing",
"route": "Oculair gebruik",
"soort": "RVG",
"source": "cbg_meb",
"smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h09368_smpc.pdf",
"strength": null,
"atc_label": "Pilocarpine",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg09368",
"excipients": [
"WATER, GEZUIVERD"
],
"substances": [
"PILOCARPINE NITRAAT"
],
"leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h09368.pdf",
"authorised_at": "1982/01/19",
"procedure_number": null,
"dispensing_status": "Uitsluitend recept",
"registration_number": "09368",
"additional_monitoring": "N"
}See everything about pilocarpine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.